Karl Chalabala's Stock Ratings

UBS Analyst

Karl Chalabala is an analyst at UBS. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 04/25/2025

Overall Average Return

-10.2%

Smart Score

30%

Overall Average Return Percentile

22nd

Number of Ratings

8
Buy NowGet Alert
11/07/2024FOLDBuy Now
Amicus Therapeutics
$7.34186.1%
Karl Chalabala30%
$19 → $21MaintainsBuyGet Alert
05/10/2024FOLDBuy Now
Amicus Therapeutics
$7.34158.86%
Karl Chalabala30%
$20 → $19MaintainsBuyGet Alert
09/29/2023FOLDBuy Now
Amicus Therapeutics
$7.34172.48%
Karl Chalabala30%
$19 → $20MaintainsBuyGet Alert
08/09/2023FOLDBuy Now
Amicus Therapeutics
$7.34158.86%
Karl Chalabala30%
$17 → $19MaintainsBuyGet Alert
03/02/2023FOLDBuy Now
Amicus Therapeutics
$7.34131.61%
Karl Chalabala30%
$15 → $17MaintainsBuyGet Alert
02/23/2023SCCOBuy Now
Southern Copper
$94.28-45.91%
Karl Chalabala30%
$46.63 → $49.55MaintainsSellGet Alert
08/14/2017GPORBuy Now
Gulfport Energy
$175.00-89.71%
Karl Chalabala30%
$21 → $18MaintainsBuyGet Alert
08/14/2017CRKBuy Now
Comstock Resources
$18.39-34.75%
Karl Chalabala30%
$14 → $12MaintainsBuyGet Alert